A collaborator and paid consultant of Cassava Sciences, Hoau-Yan Wang, has been indicted for defrauding the National Institutes of Health in grant applications supporting the company’s Alzheimer’s drug, simufilam. Wang, a neuroscientist, published key papers supporting the drug’s effectiveness, but his work has been questioned by outside researchers for containing fabricated and falsified data. The Justice Department accused Wang of securing $16 million in NIH funding through fraudulent grant applications. The indictment states that the purpose of the scheme was for Wang to enrich himself through false statements. This raises concerns about the integrity of the research supporting Cassava’s Alzheimer’s therapy.
Source link
Cassava Sciences collaborator charged with defrauding NIH
